ElevateBio | Evaluate

But, with an ever-growing proportion of the cash going to a select few, the gulf between the haves and the have-nots is widening.

Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.

May 09, 2023

A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.

January 05, 2022

While biotech indices fell, 2021 saw private companies raise the largest amount of venture capital ever.

April 07, 2021

With a record $7.1bn raised in the first quarter the cash available to private drug developers shows no signs of drying up.

Evaluate